Sanofi Consumer Healthcare India Ltd
Sanofi Consumer Healthcare India Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Guidance rank: #24 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Sanofi Consumer Healthcare India Ltd Q2 FY27 key numbers
- Revenue
- Q3 2026 revenue: ₹2,631 million, a 12% year-on-year (Y-o-Y) growth.
As stated in Sanofi Consumer Healthcare India Ltd's Q2 FY27 results statement · published 29 Oct 2026. Reported figures, not investment advice.
Based on Sanofi Consumer Healthcare India Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Q3 2026 revenue: ₹2,631 million, a 12% year-on-year (Y-o-Y) growth. EBITDA for Q3 2026: ₹1,027 million (Profit before tax and exceptional items); Year-on-year growth: 22% (from ₹841 million in Q3 2025).
From Sanofi Consumer Healthcare India Ltd's Q2 FY27 earnings-call transcript · updated 29 Oct 2026.
Revenue & Sales Performance
- Q3 2026 revenue: ₹2,631 million, a 12% year-on-year (Y-o-Y) growth.
- Domestic sales grew by 19% Y-o-Y.
- Profit Before Tax (PBT) for Q3 2026 was ₹1,027 million, up 22% Y-o-Y.
- Earnings Per Share (EPS) grew by 22% Y-o-Y, driven by revenue increase.
- Revenue from operations for the nine months ended September 2026 was ₹7,280 million, a 16% Y-o-Y growth.
2 more points from Sanofi Consumer Healthcare India Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sanofi Consumer Healthcare India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Sanofi Consumer Healthcare India Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sanofi Consumer Healthcare India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Sanofi Consumer Healthcare India Ltd said on order book & pipeline — free account, 30 seconds.
Sanofi Consumer Healthcare India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹263 Cr, net profit ₹77 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sanofi Consumer Healthcare India Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aarti Pharmalabs Ltd (Q2 FY27)
41,833.48 lakhs in the quarter ended 30th September 2025, reflecting approximately a 46% year-on-year increase. Key results statement takeaways from Aarti Pharm
- Sudeep Pharma Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations:** Rs 196.7 crore . Key investor presentation takeaways from Sudeep Pharma Ltd's Q2 FY27 investor presentation — and how it rank
- Jagsonpal Pharmaceuticals Ltd (Q2 FY27)
Q2FY27 consolidated revenue: ₹964 Mn, up 29% YoY . Key investor presentation takeaways from Jagsonpal Pharmaceuticals Ltd's Q2 FY27 investor presentation — and
- Zota Health Care Ltd (Q2 FY27)
Revenue from Operations for Q2FY27 is ₹19,933.14 lakhs, up 54.58% YoY from ₹12,894.82 lakhs in Q2FY26. Key investor presentation takeaways from Zota Health Care
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sanofi Consumer Healthcare India Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sanofi Consumer Healthcare India Ltd Q2 FY27 results?
Q3 2026 revenue: ₹2,631 million, a 12% year-on-year (Y-o-Y) growth. EBITDA for Q3 2026: ₹1,027 million (Profit before tax and exceptional items); Year-on-year growth: 22% (from ₹841 million in Q3 2025).
What is Sanofi Consumer Healthcare India Ltd share price analysis?
Sanofi Consumer Healthcare India Ltd currently shows a neutral. The stock trades at a P/E of 28.8 with a market cap of ₹7,652 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Sanofi Consumer Healthcare India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.